The introduction of tyrosine kinase inhibitors (TKI) directed against the epidermal growth factor receptor (EGFR), an oncogenic driver pathway promoting cell growth and division, led to a shift in the treatment paradigm of EGFR mutation positive NSCLC, and, ultimately to an acceleration of the development of targeted therapies against other oncogenic driver mutation targets (2–5). Here, EGFR is linked to non-small cell lung carcinoma.